ClinicalTrials.gg
Active, not recruitingNCT03937154Updated Oct 19, 2026

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

A Phase 3 interventional study of Romiplostim and Placebo in Chemotherapy-induced Thrombocytopenia, sponsored by Amgen. Active, not recruiting at 34 sites in 10 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026No longer in 8 countries105 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen — 2 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Amgen.

Enrollment
16th of 31
145 · median 145
Started
2020
the only one that year
Phase 3
8 of 40
1 open now
Registered
27th of 40
by date

Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 16th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 3, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, or all of them as a file.
02

Study summary

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

Read the detailed description

This is a phase 3, randomized, placebo-controlled, multicenter, international study for the treatment of CIT in adult subjects receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer. Subjects must have a platelet count ≤ 85 x 10\^9/L on day 1 of the study. The study will consist of a screening period of up to 4 weeks, a treatment period long enough to allow for assessment of 3 planned cycles of chemotherapy, a follow-up visit, and long-term follow-up (LTFU). Given that subjects are required to have 3 remaining planned cycles of chemotherapy, the chemotherapy cycles may be 3 or 4 weeks in duration, and the investigational product dose adjustment guidelines allow for up to 12 weeks of dosing before a subject is declared a non-responder, the majority of study subjects will receive investigational product for a range of 10-24 weeks.

03

Conditions studied

  • Chemotherapy-induced Thrombocytopenia

Keywords

  • Chemotherapy-induced thrombocytopenia
  • Non-small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study-specific activities/procedures or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
  • Males or females greater than or equal to 18 years of age at signing of the informed consent.
  • Documented active stage I, II, III or IV locally advanced or of the following tumor types: NSCLC, breast cancer, or ovarian cancer (includes fallopian tube epithelial carcinomas and peritoneal epithelial carcinoma of unknown primary), or any stage recurrent disease. Patients with documented locally advanced (stage III) NSCLC should not be amenable to definitive treatment with chemoradiation and/or surgery.
  • Subjects must be receiving cancer treatment with 21- or 28-day cycles, using one of the following carboplatinum-based combination chemotherapy regimens: carboplatin/gemcitabine based, carboplatin/pemetrexed based, carboplatin/liposomal doxorubicin based or carboplatin/taxane based (which includes either paclitaxel, nab-paclitaxel, or docetaxel) or single agent chemotherapy regimen with any of the above mentioned drugs. Use of combination regimens with one of the above carboplatinum-based regimens is permitted with (1) anti-angiogenic agents (such as bevacizumab); (2) targeted therapy (such as anti-epidermal growth factor agents or anti- human epidermal growth factor receptor 2) or (3) . Cycle duration is based on intervals between day 1 of chemotherapy cycles (overlapping with carboplatin intervals) every 21 or 28 day cycles for single agent regimens. OR, Subjects must have CIT from a non-protocol chemotherapy regimen, planning to start treatment with one of the above protocol chemotherapy regimens which has been delayed ≥ 1 week due to CIT.
  • Subjects must have a local count ≤ 85 x 109/L on day 1 of the study.
  • Subjects must be at least 21 or 28 days removed from the start of the chemotherapy cycle immediately prior to study day 1 if receiving a 21-day or 28-day cycle chemotherapy regimen, respectively.
  • Subjects must have at least 3 remaining planned cycles of chemotherapy at study enrollment.
  • (ECOG) performance status of 0, 1, or 2.

Exclusion criteria

Exclusion Criteria:

  • Acute lymphoblastic leukemia.
  • Acute myeloid leukemia.
  • Any myeloid .
  • Myelodysplastic syndrome. Baseline bone marrow is not required to rule out MDS. However, if a bone marrow biopsy and cytogenetics were performed as part of diagnostic or staging work-up, these results will be collected to confirm.
  • Myeloproliferative disease.
  • Multiple myeloma.
  • Within 4 months prior to enrollment, any history of active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, (ECG) abnormalities, screening ECG with (QTc) interval of greater than 470 msec, pericardial disease, or myocardial infarction.
  • Major surgery less than or equal to 28 days or minor surgery less than or equal to 3 days prior to enrollment.
  • New or uncontrolled venous thromboembolism or thrombotic events within 3 months prior to screening. To be eligible, subjects must have received at least 14 days of anticoagulation for a new thrombotic event and considered to be stable and suitable for continued therapeutic anticoagulation during trial participation.
  • History of arterial thrombotic events (eg, myocardial ischemia, , or stroke) within 6 months prior to screening.
  • Evidence of active infection within 2 weeks prior to the first dose of study treatment.
  • Known infection with any detectable viral load at screening. Subjects without a documented diagnosis in their medical history will require a local laboratory assessment at screening. If local laboratory results are not available use central laboratory results.
  • Known active of chronic or infection. Subjects without a documented diagnosis in their medical history will require a local laboratory assessment at screening. If local laboratory results are not available use central laboratory results. Hepatitis B and C infection is based on the following results:
  • Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B).
  • Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA suggests occult hepatitis B.
  • Positive hepatitis C virus antibody: hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C.
  • In addition to the conditions listed in exclusion criteria 201 through 206, secondary malignancy within the past 5 years except:
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  • Adequately treated cervical carcinoma in situ without evidence of disease.
  • Adequately treated breast ductal carcinoma in situ without evidence of disease.
  • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
  • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.
  • Malignancy treated with curative intent and with no known active disease present for greater than or equal to 3 years before enrollment and felt to be at low risk for recurrence by the treating physician (excluding malignancies listed in exclusion criteria 201 - 206).
  • Thrombocytopenia due to another etiology other than CIT (eg, chronic liver disease, prior history of immune thrombocytopenia purpura).
  • Any combined modality regimen containing radiation therapy or surgery occurring concomitantly with chemotherapy or where radiation therapy is planned during the cycle preceding 3 planned on-study cycles of chemotherapy.

Prior/Concomitant Therapy:

- Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor, eltrombopag, recombinant human TPO, any other TPO receptor agonist, or any producing agent.

Prior/Concurrent Clinical Study Experience - Currently receiving (or plan to receive) treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.

Diagnostic Assessments

  • Anemia ( \< 80 g/L [8 g/dL]) on the day of initiation of investigational product as assessed by local labs. Use of red cell transfusions and erythropoietic stimulating agents is permitted throughout the study as per institutional guidelines.
  • Neutropenia ( less than 1 x 10 9/L) on the day of initiation of investigational product as assessed by local labs. Use of granulocyte-colony stimulating factor is permitted throughout the study as per institutional guidelines.
  • Abnormal renal function with less than 30 mL/min using the Cockcroft-Gault estimated creatinine clearance as assessed by local laboratory. If local laboratory results are not available use central laboratory results.

during screening.

- Abnormal liver function (total greater than 3X ; [ALT] or aspartate aminotransferase [AST] greater than 3X ULN for subjects without liver or greater than or equal to 5X ULN for subjects with liver metastases) as assessed by local laboratory during screening. If local laboratory results are not available use central laboratory results.

Other Exclusions

  • Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 7 months after treatment (and chemotherapy) discontinuation (females of should only be included after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test.)
  • Females of childbearing potential unwilling to use a highly effective method of during treatment and for an additional 7 months after treatment (and chemotherapy) discontinuation. Refer to Appendix 5 for additional contraceptive information.
  • Males unwilling to use contraception* (male condom or sexual abstinence) or their female partner(s) of childbearing potential who are unwilling to use a highly effective method of contraception during treatment (and chemotherapy) and for an additional 7 months after treatment (and chemotherapy) discontinuation. *If the male's sole partner is of non-childbearing potential, he is not required to use additional forms of contraception during the study.
  • Subject has known sensitivity to any of the products to be administered during dosing.
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, COAs) to the best of the subject and investigator's knowledge.
  • History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment (and chemotherapy) and for an additional 7 months after treatment (and chemotherapy) discontinuation.
  • Male subjects unwilling to abstain from donating sperm during treatment (and chemotherapy) and for an additional 7 months after treatment (and chemotherapy) discontinuation.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Romiplostim

    The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

    Drug: Romiplostim

  • Placebo comparator
    Placebo

    The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

    Drug: Placebo

Interventions

  • This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer

    Also known as: Nplate

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Incidence of either a chemotherapy dose delay or reduction

    No thrombocytopenia-induced modification of any myelosuppressive agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 109/L

    Time frame: 48 days

Secondary outcomes

  1. Depth of Platelet Count

    the depth of the platelet count nadir from the start of the first on-study chemotherapy cycle through the end of the treatment period

    Time frame: 48 days

  2. Time to First platelet response

    The time to first platelet response, defined by platelet count ≥ 100 x 109/L in the absence of platelet transfusions during the preceding 7 days

    Time frame: 7 days

  3. the duration-adjusted event rate of ≥ grade 2 bleeding events

    the duration-adjusted event rate of ≥ grade 2 bleeding events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading scale

    Time frame: 48 days

  4. Overall survival

    1-year overall survival

    Time frame: 1 Year

  5. Proportion of subjects with at leat 1 incidence of platelet transfusion

    platelet transfusion(s) during the treatment period

    Time frame: 48 days

  6. proportion of patients achieving platelet count >= 100 x 10 9/L

    7 days after 3rd dose of IP with no transfusions in preceding 7 days

    Time frame: 7 days

  7. The subject incidence of adverse events

    Through end of study, up to 36 months. It will be counted in as an adverse event: any treatment - emergent adverse events, fatal adverse events, serious adverse events, or clinically significant changes in laboratory values.

    Time frame: 36 months

  8. Number of subjects who develop anti-romiplostim antibodies

    Through end of study up to 36 months

    Time frame: 36 Months

  9. Number of subjects who develop anti-TPO antibodies

    Through end of study, up to 36 months

    Time frame: 36 months

  10. Number of subjects who experience myelodysplastic syndromes

    Through end of study, up to 36 months

    Time frame: 36 months

  11. Number of subjects who experience secondary malignancies

    Through end of study, up to 36 months

    Time frame: 36 months

07

Study locations

34 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Mar 2026, 72 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 72 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
May 3, 2019
StartActual
Feb 26, 2020
Primary completionActual
Mar 10, 2026
CompletionEst.
Feb 23, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
105 sites removed; no longer in Austria, Bulgaria, Chile, Colombia, Hungary and 3 more
All 8 countries

Austria, Bulgaria, Chile, Colombia, Hungary, Portugal, Russia, Ukraine

Show 105 removed
  • Saint Bernards Medical Center · Jonesboro, United States
  • Los Angeles Cancer Network · Anaheim, United States
  • University of California Irvine · Orange, United States
  • Colorado West Healthcare System dba Grand Valley Oncology · Grand Junction, United States
  • University of Miami School of Medicine · Miami, United States
  • Ocala Oncology Center · Ocala, United States
  • Mid Florida Hematology and Oncology Centers PA · Orange City, United States
  • Saint Alphonsus Regional Medical Center · Boise, United States
  • University of Chicago · Chicago, United States
  • Orchard Healthcare Research Inc · Skokie, United States
  • Christus Saint Frances Cabrini Hospital · Alexandria, United States
  • University Medical Center New Orleans · New Orleans, United States
  • Christus Highland Cancer Treatment Center · Shreveport, United States
  • Mercy Medical Center · Baltimore, United States
  • American Oncology Partners, PA · Bethesda, United States
  • Massachusetts General Hospital · Boston, United States
  • Hattiesburg Clinic Hematology/Oncology · Hattiesburg, United States
  • Oncology Hematology Associates · Springfield, United States
  • Great Falls Clinic · Great Falls, United States
  • Nebraska Cancer Specialists · Omaha, United States
  • Regional Cancer Care Associates · Sparta, United States
  • Broome Oncology LLC · Binghamton, United States
  • Saint Lukes University Health Network · Bethlehem, United States
  • The Center for Cancer and Blood Disorders · Fort Worth, United States
  • Yakima Valley Memorial Hospital · Yakima, United States
  • Centro Medico Austral · Buenos Aires, Argentina
  • Centro de Diagnostico Investigacion y Tratamiento · Salta, Argentina
  • Medizinische Universitaet Innsbruck · Innsbruck, Austria
  • Instituto de Oncologia do Parana · Curitba, Brazil
  • Centro de Pesquisa da Serra Gaucha - Cepesg · Caxias do Sul, Brazil
  • …and 75 more on the registry record
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    105 sites removed; no longer in Austria, Bulgaria, Chile, Colombia, Hungary and 3 more
    All 8 countries

    Austria, Bulgaria, Chile, Colombia, Hungary, Portugal, Russia, Ukraine

    Show 105 removed
    • Saint Bernards Medical Center · Jonesboro, United States
    • Los Angeles Cancer Network · Anaheim, United States
    • University of California Irvine · Orange, United States
    • Colorado West Healthcare System dba Grand Valley Oncology · Grand Junction, United States
    • University of Miami School of Medicine · Miami, United States
    • Ocala Oncology Center · Ocala, United States
    • Mid Florida Hematology and Oncology Centers PA · Orange City, United States
    • Saint Alphonsus Regional Medical Center · Boise, United States
    • University of Chicago · Chicago, United States
    • Orchard Healthcare Research Inc · Skokie, United States
    • Christus Saint Frances Cabrini Hospital · Alexandria, United States
    • University Medical Center New Orleans · New Orleans, United States
    • Christus Highland Cancer Treatment Center · Shreveport, United States
    • Mercy Medical Center · Baltimore, United States
    • American Oncology Partners, PA · Bethesda, United States
    • Massachusetts General Hospital · Boston, United States
    • Hattiesburg Clinic Hematology/Oncology · Hattiesburg, United States
    • Oncology Hematology Associates · Springfield, United States
    • Great Falls Clinic · Great Falls, United States
    • Nebraska Cancer Specialists · Omaha, United States
    • Regional Cancer Care Associates · Sparta, United States
    • Broome Oncology LLC · Binghamton, United States
    • Saint Lukes University Health Network · Bethlehem, United States
    • The Center for Cancer and Blood Disorders · Fort Worth, United States
    • Yakima Valley Memorial Hospital · Yakima, United States
    • Centro Medico Austral · Buenos Aires, Argentina
    • Centro de Diagnostico Investigacion y Tratamiento · Salta, Argentina
    • Medizinische Universitaet Innsbruck · Innsbruck, Austria
    • Instituto de Oncologia do Parana · Curitba, Brazil
    • Centro de Pesquisa da Serra Gaucha - Cepesg · Caxias do Sul, Brazil
    • …and 75 more on the registry record
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03937154
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 3, 2019
Start date
Feb 26, 2020
Primary completion
Mar 10, 2026
Completion
Feb 23, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion